Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Alterity secures option underwriting as it prepares for pivotal MSA trial

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

Australia

◆ Source

Read at biotechdispatch.com.au →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

Alterity Therapeutics secured underwriting for up to $4.2 million to fund its Phase 3 clinical trial of ATH434 for multiple system atrophy, strengthening its financial position ahead of this key milestone.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new funding route open that backs critical late-stage neurodegenerative drug trials. This underwriting deal lets you push Phase 3 without a cash crunch and should be locked in before option expiry.

◆ Coverage

1 source · 31 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialfundraisingunderwritingneurodegenerativephase-3